Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalotuzumab + Etoposide/Cisplatin in Extensive Stage SCLC
NCT00869752Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Dec 2009
- Primary completion
- Mar 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of dalotuzumab in small cell lung cancer (SCLC), sponsored by Canadian Cancer Trials Group. Started Dec 2009; status: completed.
02
Drugs
dalotuzumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00869752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00869752.